SCYNEXIS Reports Successful Completion of Pre-NDA Meetings with the FDA Regarding Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis Jul 29, 2020
SCYNEXIS Announces Four Posters Presented at ASM Microbe 2020 Highlighting the Potential Clinical Utility of Ibrexafungerp Jul 22, 2020
SCYNEXIS to Host A Key Opinion Leader Discussion on the Immediate Need in Treating Women with Vaginal Yeast Infections Jul 9, 2020
SCYNEXIS Strengthens Leadership Team with Appointment of Jim Maffezzoli as Vice President of Marketing and Sales Jun 2, 2020
SCYNEXIS Announces Six Abstracts Published by 30th ECCMID Highlighting the Potential Clinical Utility of Ibrexafungerp May 6, 2020
SCYNEXIS to Participate in Antifungals Panel at Maxim Group’s Infectious Disease Virtual Conference: The Renaissance of the Anti-infective Sector Apr 28, 2020
SCYNEXIS Announces Positive Top-Line Results from its Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection) Apr 21, 2020
